Condition: Natural Killer T-cell Lymphoma · Sponsor: Sun Yat-sen University
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.
This description comes directly from the study's public registry record.
Qingqing Cai, MD. PhD. · 0086-20-87342823 · caiqq@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Beijing Tongren Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06733051